Generic Glyxambi Availability
Last updated on Apr 10, 2024.
Glyxambi is a brand name of empagliflozin/linagliptin, approved by the FDA in the following formulation(s):
GLYXAMBI (empagliflozin; linagliptin - tablet;oral)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: January 30, 2015
Strength(s): 10MG;5MG [RLD], 25MG;5MG [RLD]
Has a generic version of Glyxambi been approved?
No. There is currently no therapeutically equivalent version of Glyxambi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Glyxambi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical composition, methods for treating and uses thereof
Patent 10,258,637
Issued: April 16, 2019
Inventor(s): Broedl Uli Christian & Macha Sreeraj & von Eynatten Maximilian & Woerle Hans-Juergen
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Patent expiration dates:
- April 3, 2034✓
- April 3, 2034
-
Pharmaceutical composition, methods for treating and uses thereof
Patent 10258637*PE
Issued: April 16, 2019
Inventor(s): Broedl Uli Christian & Macha Sreeraj & von Eynatten Maximilian & Woerle Hans-Juergen
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Patent expiration dates:
- October 3, 2034
- October 3, 2034
-
DPP IV inhibitor formulations
Patent 11,033,552
Issued: June 15, 2021
Inventor(s): Kohlrausch Anja & Romer Patrick & Seiffert Gerd
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.
Patent expiration dates:
- May 4, 2027✓
- May 4, 2027
-
DPP IV inhibitor formulations
Patent 11033552*PE
Issued: June 15, 2021
Inventor(s): Kohlrausch Anja & Romer Patrick & Seiffert Gerd
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.
Patent expiration dates:
- November 4, 2027
- November 4, 2027
-
Patent 11,090,323
Patent expiration dates:
- April 3, 2034✓
- April 3, 2034
-
Patent 11090323*PE
Patent expiration dates:
- October 3, 2034
- October 3, 2034
-
Patent 11,833,166
Patent expiration dates:
- April 3, 2034✓
- April 3, 2034✓
- April 3, 2034
-
Patent 7,407,955
Patent expiration dates:
- May 2, 2025✓✓
- May 2, 2025
-
Patent 7407955*PED
Patent expiration dates:
- November 2, 2025✓
- November 2, 2025
-
Patent 7,579,449
Patent expiration dates:
- August 1, 2028✓
- August 1, 2028
-
Patent 7579449*PED
Patent expiration dates:
- February 1, 2029✓
- February 1, 2029
-
Patent 7,713,938
Patent expiration dates:
- April 15, 2027✓✓
- April 15, 2027
-
Patent 7713938*PED
Patent expiration dates:
- October 15, 2027✓
- October 15, 2027
-
Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Patent 8,551,957
Issued: October 8, 2013
Inventor(s): Dugi Klaus & Mark Michael & Thomas Leo & Himmelsbach Frank
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to a pharmaceutical composition according to the claim comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Patent expiration dates:
- October 14, 2029✓✓
- October 14, 2029
-
Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Patent 8551957*PED
Issued: October 8, 2013
Inventor(s): Dugi Klaus & Mark Michael & Thomas Leo & Himmelsbach Frank
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to a pharmaceutical composition according to the claim comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Patent expiration dates:
- April 14, 2030✓
- April 14, 2030
-
Uses of DPP-IV inhibitors
Patent 8,673,927
Issued: March 18, 2014
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- May 4, 2027✓✓
- May 4, 2027
-
Uses of DPP-IV inhibitors
Patent 8673927*PED
Issued: March 18, 2014
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- November 4, 2027✓
- November 4, 2027
-
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent 8,883,805
Issued: November 11, 2014
Inventor(s): Pfrengle Waldemar & Pachur Thorsten & Nicola Thomas & Duran Adil
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
Patent expiration dates:
- November 26, 2025✓
- November 26, 2025
-
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent 8883805*PED
Issued: November 11, 2014
Inventor(s): Pfrengle Waldemar & Pachur Thorsten & Nicola Thomas & Duran Adil
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
Patent expiration dates:
- May 26, 2026✓
- May 26, 2026
-
Uses of DPP IV inhibitors
Patent 9,173,859
Issued: November 3, 2015
Inventor(s): Dugi Klaus & Himmelsbach Frank & Mark Michael
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- May 4, 2027✓✓✓
- May 4, 2027
-
Pharmaceutical composition, methods for treating and uses thereof
Patent 9,949,998
Issued: April 24, 2018
Inventor(s): Broedl Uli Christian & Macha Sreeraj & von Eynatten Maximilian & Woerle Hans-Juergen
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Patent expiration dates:
- June 11, 2034✓
- June 11, 2034
More about Glyxambi (empagliflozin / linagliptin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (22)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antidiabetic combinations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.